

Step Therapy Criteria

GLP1-INSULIN

Products Affected

Step 2:

- SOLIQUA SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML SUBCUTANEOUS
- XULTOPHY SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML SUBCUTANEOUS

Details

Criteria	<p>Claim will pay automatically for Xultophy OR Soliqua if enrollee has a paid claim for at least a 1 day supply for step level 1 agent (LANTUS, LEVEMIR, OZEMPIC, TOUJEO, TRESIBA, OR VICTOZA). Otherwise, Xultophy AND Soliqua requires a step therapy exception request indicating: (1) history of inadequate treatment response with step 1 agent, OR (2) history of adverse event with step 1 agent, OR (3) step 1 agent is contraindicated.</p>
-----------------	--

Step Therapy Criteria

PPI

Products Affected

Step 2:

- DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL
- DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL

Details

Criteria	Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 days supply of lansoprazole, omeprazole, pantoprazole, or rabeprazole in the past. Otherwise, Dexilant requires a step therapy exception request indicating: (1) history of inadequate treatment response with lansoprazole, omeprazole, pantoprazole, or rabeprazole, OR (2) history of adverse event with lansoprazole, omeprazole, pantoprazole, or rabeprazole, OR (3) lansoprazole, omeprazole, pantoprazole, or rabeprazole is contraindicated.
-----------------	---

Step Therapy Criteria

RYTARY

Products Affected

Step 2:

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

Details

Criteria	Claim will pay automatically for Rytary if enrollee has a paid claim for at least a 1 days supply of step level 1 agent (CARBIDOPA-LEVODOPA OR CARBIDOPA-LEVODOPA-ENTACAPONE). Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with step 1 agent, OR (2) history of adverse event with step 1 agent, OR (3) step 1 agent is contraindicated.
-----------------	---

Step Therapy Criteria

TRELEGY

Products Affected

Step 2:

- TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/INH INHALATION

Details

Criteria	Claim will pay automatically for Trelegy if enrollee has a paid claim for at least 1 day supply of Advair Diskus, Anoro Ellipta, Breo Ellipta, Serevent Diskus, Spiriva HandiHaler, Spiriva Respimat or Stiolto in the past. Otherwise, Trelegy will require a step therapy exception request indicating: (1) history of inadequate treatment response with STEP 1 Agent, OR (2) history of adverse event with STEP 1 Agent, OR (3) STEP 1 Agent is contraindicated.
----------	--

Step Therapy Criteria

TRINTELLIX

Products Affected

Step 2:

- TRINTELLIX TABLET 10 MG ORAL
- TRINTELLIX TABLET 5 MG ORAL
- TRINTELLIX TABLET 20 MG ORAL

Details

Criteria	Claim will pay automatically for trintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past. Otherwise, trintellix requires a step therapy exception request indicating: (1) history of inadequate treatment response with any 2 generic formulary antidepressants , OR (2) history of adverse event with any 2 generic formulary antidepressants , OR (3) any 2 generic formulary antidepressants are contraindicated.
-----------------	--

Step Therapy Criteria

ULORIC

Products Affected

Step 2:

- ULORIC TABLET 40 MG ORAL
- ULORIC TABLET 80 MG ORAL

Details

Criteria	Claim will pay automatically for Uloric if enrollee has a paid claim for at least a 1 days supply of Allopurinol in the past. Otherwise, Uloric requires a step therapy exception request indicating: (1) history of inadequate treatment response with Allopurinol, OR (2) history of adverse event with Allopurinol, OR (3) Allopurinol is contraindicated.
----------	---

Step Therapy Criteria

Index

D

DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL.....	2
DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL.....	2

R

RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL	3
RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL	3
RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL	3
RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL	3

S

SOLIQUA SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML SUBCUTANEOUS.....	1
---	---

T

TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 100- 62.5-25 MCG/INH INHALATION	4
TRINTELLIX TABLET 10 MG ORAL.....	5
TRINTELLIX TABLET 20 MG ORAL.....	5
TRINTELLIX TABLET 5 MG ORAL.....	5

U

ULORIC TABLET 40 MG ORAL	6
ULORIC TABLET 80 MG ORAL	6

X

XULTOPHY SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML SUBCUTANEOUS.....	1
---	---